Literature DB >> 27337475

Clostridium difficile Infection.

Jae Hyun Shin1, Esteban Chaves-Olarte2, Cirle A Warren1.   

Abstract

Clostridium difficile is an anaerobic, Gram-positive, spore-forming, toxin-secreting bacillus that has long been recognized to be the most common etiologic pathogen of antibiotic-associated diarrhea. C. difficile infection (CDI) is now the most common cause of health care-associated infections in the United States and accounts for 12% of these infections (Magill SS et al., N Engl J Med370:1198-1208, 2014). Among emerging pathogens of public health importance in the United States, CDI has the highest population-based incidence, estimated at 147 per 100,000 (Lessa FC et al., N Engl J Med372:825-834, 2015). In a report on antimicrobial resistance, C. difficile has been categorized by the Centers for Disease Control and Prevention as one of three "urgent" threats (http://www.cdc.gov/drugresistance/threat-report-2013/). Although C. difficile was first described in the late 1970s, the past decade has seen the emergence of hypertoxigenic strains that have caused increased morbidity and mortality worldwide. Pathogenic strains, host susceptibility, and other regional factors vary and may influence the clinical manifestation and approach to intervention. In this article, we describe the global epidemiology of CDI featuring the different strains in circulation outside of North America and Europe where strain NAP1/027/BI/III had originally gained prominence. The elderly population in health care settings has been disproportionately affected, but emergence of CDI in children and healthy young adults in community settings has, likewise, been reported. New approaches in management, including fecal microbiota transplantation, are discussed.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27337475      PMCID: PMC8118380          DOI: 10.1128/microbiolspec.EI10-0007-2015

Source DB:  PubMed          Journal:  Microbiol Spectr        ISSN: 2165-0497


  212 in total

Review 1.  A review of mortality due to Clostridium difficile infection.

Authors:  J A Karas; D A Enoch; S H Aliyu
Journal:  J Infect       Date:  2010-03-31       Impact factor: 6.072

2.  Carriage of Clostridium difficile in free-living South American coati (Nasua nasua) in Brazil.

Authors:  Rodrigo Otávio Silveira Silva; Lara Ribeiro de Almeida; Carlos Augusto Oliveira Junior; Danielle Ferreira de Magalhães Soares; Pedro Lúcio Lithg Pereira; Maja Rupnik; Francisco Carlos Faria Lobato
Journal:  Anaerobe       Date:  2014-09-27       Impact factor: 3.331

Review 3.  Vaccines against Clostridium difficile.

Authors:  Rosanna Leuzzi; Roberto Adamo; Maria Scarselli
Journal:  Hum Vaccin Immunother       Date:  2014-03-17       Impact factor: 3.452

4.  Prevalence of Clostridium difficile in pseudomembranous and antibiotic-associated colitis in north India.

Authors:  A Ayyagari; P Sharma; S Mehta; K C Agarwal
Journal:  J Diarrhoeal Dis Res       Date:  1986-09

5.  Prevalence and clinical course of Clostridium difficile infection in a tertiary-care hospital: a retrospective analysis.

Authors:  Meghraj Ingle; Abhijit Deshmukh; Devendra Desai; Philip Abraham; Anand Joshi; Camilla Rodrigues; Ranjit Mankeshwar
Journal:  Indian J Gastroenterol       Date:  2011-05-07

6.  Fecal lactoferrin, interleukin-1beta, and interleukin-8 are elevated in patients with severe Clostridium difficile colitis.

Authors:  T S Steiner; C A Flores; T T Pizarro; R L Guerrant
Journal:  Clin Diagn Lab Immunol       Date:  1997-11

7.  Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection.

Authors:  Ilan Youngster; George H Russell; Christina Pindar; Tomer Ziv-Baran; Jenny Sauk; Elizabeth L Hohmann
Journal:  JAMA       Date:  2014-11-05       Impact factor: 56.272

8.  Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial.

Authors:  Oliver A Cornely; Derrick W Crook; Roberto Esposito; André Poirier; Michael S Somero; Karl Weiss; Pamela Sears; Sherwood Gorbach
Journal:  Lancet Infect Dis       Date:  2012-02-08       Impact factor: 25.071

9.  Distribution of Clostridium difficile strains from a North American, European and Australian trial of treatment for C. difficile infections: 2005-2007.

Authors:  Adam K Cheknis; Susan P Sambol; David M Davidson; Kristin J Nagaro; Maria C Mancini; G Aida Hidalgo-Arroyo; Jon S Brazier; Stuart Johnson; Dale N Gerding
Journal:  Anaerobe       Date:  2009-09-06       Impact factor: 3.331

10.  Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial.

Authors:  Stephen J Allen; Kathie Wareham; Duolao Wang; Caroline Bradley; Hayley Hutchings; Wyn Harris; Anjan Dhar; Helga Brown; Alwyn Foden; Michael B Gravenor; Dietrich Mack
Journal:  Lancet       Date:  2013-08-08       Impact factor: 79.321

View more
  5 in total

Review 1.  Advances in the diagnosis and treatment of Clostridium difficile infections.

Authors:  Zhong Peng; Lifen Ling; Charles W Stratton; Chunhui Li; Christopher R Polage; Bin Wu; Yi-Wei Tang
Journal:  Emerg Microbes Infect       Date:  2018-02-07       Impact factor: 7.163

2.  Outcomes of Continuous Enteral Vancomycin Infusion in Intensive Care Unit Patients: A Novel Treatment Modality for Severe Clostridium Difficile Colitis.

Authors:  Haley Peters; Arslan Iqbal; Emily Miller; Sana Khalid; Omar Rahman
Journal:  Cureus       Date:  2022-03-05

3.  A Novel Bacteriophage Lysin-Human Defensin Fusion Protein Is Effective in Treatment of Clostridioides difficile Infection in Mice.

Authors:  Zhong Peng; Shaohui Wang; Mussie Gide; Duolong Zhu; Hiran Malinda Lamabadu Warnakulasuriya Patabendige; Chunhui Li; Jianfeng Cai; Xingmin Sun
Journal:  Front Microbiol       Date:  2019-01-11       Impact factor: 5.640

Review 4.  Imaging Inflammation and Infection in the Gastrointestinal Tract.

Authors:  Alex N Frickenstein; Meredith A Jones; Bahareh Behkam; Lacey R McNally
Journal:  Int J Mol Sci       Date:  2019-12-30       Impact factor: 5.923

5.  Bacteriophage endolysins as a potential weapon to combat Clostridioides difficile infection.

Authors:  Shakhinur Islam Mondal; Lorraine A Draper; R Paul Ross; Colin Hill
Journal:  Gut Microbes       Date:  2020-11-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.